PBAC backs ADHD meds listing change

Changes to PBS restrictions for atomoxetine and guanfacine for the treatment of ADHD are being supported by the PBAC  The Pharmaceutical Benefits Advisory Committee (PBAC) is backing a move to broaden access to atomoxetine and guanfacine for attention deficit hyperactivity disorder (AHPA) through the Pharmaceutical Benefits Scheme (PBS).   The recommendation was released as part of the outcomes